Skip to main content
3SBio Inc. logo

3SBio Inc. — Investor Relations & Filings

Ticker · 1530 ISIN · KYG8875G1029 LEI · 529900P0TQC1E9Y7FN31 HKEX Manufacturing
Open in API
Filings indexed 1,491 across all filing types
Latest filing 2020-12-29 Report Publication Anno…
Country KY Cayman Islands
Listing HKEX 1530

About 3SBio Inc.

http://www.3sbio.com

3SBio Inc. is a biopharmaceutical enterprise specializing in the integrated research, development, production, and commercialization of innovative biopharmaceutical products. The company operates as a biotechnology firm, focusing on the discovery, development, manufacture, and marketing of biologics, with a particular emphasis on mammalian cell-based biopharmaceuticals. 3SBio addresses critical medical needs by providing an extensive range of products and services to markets both domestically and internationally.

Recent filings

Filing Released Lang Actions
Letter to Registered Shareholders - Notice of Publication of 2020 Interim Report
Report Publication Announcement Classification · 95% confidence The document is a letter dated 30 December 2020 from Hongkong Chinese Limited to its shareholders. It announces the publication of the 2020 Interim Report and provides instructions on how shareholders can access the report electronically via the company's website and the HKEX website. The letter also offers assistance for shareholders who have difficulty accessing the report electronically. The document does not contain the actual interim financial statements or substantive financial data but merely informs shareholders that the interim report is available online. The document length is 2445 characters, which is relatively short and consistent with an announcement rather than the report itself. According to the 'MENU VS MEAL' rule, this is a Report Publication Announcement (RPA) rather than the Interim Report (IR) itself.
2020-12-29 English
2020 Interim Report
Interim / Quarterly Report Classification · 100% confidence The document contains detailed financial statements including condensed consolidated statements of profit or loss, comprehensive income, financial position, changes in equity, and cash flows for the six months ended 30 September 2020. It also includes notes to the interim financial statements, business review, supplementary financial information, and corporate information. The presence of unaudited condensed consolidated interim financial statements for a six-month period clearly indicates this is a comprehensive interim or quarterly financial report. The document length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2021
2020-12-29 English
VOLUNTARY ANNOUNCEMENT - SUNSHINE GUOJIAN'S CIPTERBIN AND THE COMPANY'S TPIAO LISTED ON THE 2020 NATIONAL REIMBURSEMENT DRUG LIST
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the company's board regarding the acceptance of two products onto the 2020 National Reimbursement Drug List. It is a short announcement (1701 characters) and does not contain financial data, regulatory certifications, or detailed reports. It is not an annual or interim report, earnings release, or management discussion. It is an update on company product status relevant to investors and the market. Given the short length and nature as an announcement, it fits best under Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2020-12-28 English
VOLUNTARY ANNOUNCEMENT - SUNSHINE GUOJIAN SELECTS VERSEAU'S VSIG-4-TARGETED ANTIBODY AS THE SECOND PARTNERED MACROPHAGE CHECKPOINT MODULATOR IN IMMUNO-ONCOLOGY COLLABORATION
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by 3SBio Inc. regarding the selection of a monoclonal antibody targeting VSIG-4 as part of a partnership agreement with Verseau Therapeutics. It is a press release-style announcement about a collaboration and licensing agreement in the field of immuno-oncology. There are no financial statements, regulatory certifications, voting results, or management changes. The document is not a report but an announcement of a business development and partnership update. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is a voluntary announcement about a partnership and licensing program, which aligns best with a general Regulatory Filing (RNS) as a miscellaneous regulatory announcement that does not fit other specific categories.
2020-12-14 English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 November 2020
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 30/11/2020, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized share capital, issued share capital, share options, warrants, convertibles, and other share-related activities. The content focuses on changes in share capital and securities movements rather than financial performance, earnings, or management commentary. It is a regulatory filing reporting share capital movements for a specific month. The document is lengthy (15,000 characters) and contains detailed data on share capital changes, which is typical for a Major Shareholding Notification or similar capital movement report. However, it does not report on major shareholding threshold crossings but rather on monthly movements in securities and share capital. This fits best with the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues, stock splits, or other capital changes. Therefore, the document is classified as SHA with high confidence.
2020-12-02 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2020
Capital/Financing Update Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 30/11/2020 and is addressed to the Hong Kong Exchanges and Clearing Limited. It details movements in authorised share capital, issued share capital, share options, warrants, convertibles, and other share-related transactions. The content focuses on changes in the company's capital structure and share issuance activities during the month. There are no financial statements, earnings data, management discussion, or audit information. The document is a regulatory monthly return about share capital movements, which fits the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed data on capital changes, not just an announcement or a brief notice, so it is not a Report Publication Announcement or Regulatory Filing. Therefore, the best classification is CAP with high confidence.
2020-12-01 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.